WebChrontech Pharma Ab Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2009-02-02 Filing date 2010-01-29 Publication date 2011-01-06 2009-02-02 Priority to US14929909P priority Critical WebA study version is represented by a row in the table. Select two study versions to compare. One each from columns A and B. Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed.
Industry Reports Friday, May 6, 2016 - pharmafocusasia.com
WebWe are an undisputed leader in medical device IP Law, having filed more than 5,000 patent applications in the medical device arts alone, helped over 50 medical device companies get acquired or go public, and successfully litigated numerous medical device IP cases, several through trial and appeal. WebStatus: Unknown status: Phase: Phase 2: Sponsor: ChronTech Pharma AB: Start date: April 2011: End date: June 2012: Enrollment: 32 participants: Identifiers ... high country designs
WO2010086743A3 - Codon-optimised hepatitis b virus core …
WebDec 23, 2014 · Much of the work described herein has been funded by Swedish Science Council, the Swedish Cancer Foundation, the Stockholm County Council, Karolinska Institutet, and Chrontech Pharma. Conflict of interest. MS is a board member of Chrontech which holds the commercial rights to the NS3/4A-based DNA vaccine. Ethical standard WebApr 9, 2024 · CHRONTECH PHARMA AB (SWX:CTECH) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share CHRONTECH PHARMA AB … WebMar 18, 2011 · that its partner, ChronTech Pharma AB (formerly Tripep AB), has initiated a Phase IIb clinical study of its ChronVac-C DNA vaccine for hepatitis C virus (HCV), delivered by Inovio's proprietary electroporation DNA vaccine delivery technology, in combination high country desert